Grace Therapeutics, Inc.(GRCE)

$2.14—Stale · unknown old

Ask SA Chart

Grace Therapeutics, Inc.(GRCE)

NASDAQ • Last print unknown ago

$2.14—Stale · unknown old

Ask SA Chart Studio

GRCE(GRCE)

GRCE

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.15

Nov 12, 2026 · Reports before open

Revenue Estimate

$1M

FY2029E EPS$1.60

FY2030E EPS$2.40

Analyst Sentiment

Wall St. Consensus

Buy

2 analysts·Low coverage

Score

2 Buy (100%)0 Hold (0%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

2100%

Hold

00%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$4.00

+86.9%

Consensus

$4.00

+86.9%

Bull

$4.00

+86.9%

12-Month Target Range2 analysts

$4.00$4.00$4.00

Current $2.14Consensus

Current Price

$2.14

Upside to Consensus

$1.86

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+1011.11%

EPS—

FY2028

Rev+0.00%

EPS—

FY2029

Rev+1900.00%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$5M	$5M	$100M	$140M
Low	$5M	$5M	$97M	$135M
High	$5M	$5M	$103M	$145M
EBITDA Avg	$-11M	$-8M	$31M	$47M
Low	$-12M	$-8M	$30M	$45M
High	$-11M	$-7M	$33M	$49M
EBIT Avg	$-11M	$-8M	$31M	$47M
Low	$-12M	$-8M	$30M	$45M
High	$-11M	$-7M	$33M	$49M
Net Income Avg	$-11M	$-8M	$26M	$40M
Low	$-12M	$-8M	$25M	$38M
High	$-11M	$-7M	$28M	$41M
EPS Avg	$-0.68	$-0.47	$1.60	$2.40
Low	$-0.71	$-0.50	$1.53	$2.29
High	$-0.64	$-0.43	$1.67	$2.51
Analysts (Rev / EPS)	1 / 1	2 / 2	1 / 1	1 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027	Q1 2028
Revenue Avg	$1M	$2M	$4M	$5M	$6M	$396,900	$992,200
Low	$1M	$2M	$4M	$5M	$6M	$396,900	$992,200
High	$1M	$2M	$4M	$5M	$6M	$396,900	$992,200
EBITDA Avg	$-3M	$-3M	$-2M	$-2M	$-2M	$-2M	$-2M
Low	$-3M	$-3M	$-2M	$-2M	$-2M	$-2M	$-2M
High	$-3M	$-3M	$-2M	$-2M	$-2M	$-2M	$-2M
EBIT Avg	$-3M	$-3M	$-2M	$-2M	$-2M	$-2M	$-2M
Low	$-3M	$-3M	$-2M	$-2M	$-2M	$-2M	$-2M
High	$-3M	$-3M	$-2M	$-2M	$-2M	$-2M	$-2M
Net Income Avg	$-3M	$-3M	$-2M	$-2M	$-2M	$-2M	$-2M
Low	$-3M	$-3M	$-2M	$-2M	$-2M	$-2M	$-2M
High	$-3M	$-3M	$-2M	$-2M	$-2M	$-2M	$-2M
EPS Avg	$-0.15	$-0.15	$-0.12	$-0.11	$-0.10	$-0.10	$-0.10
Low	$-0.15	$-0.15	$-0.12	$-0.11	$-0.10	$-0.10	$-0.10
High	$-0.15	$-0.15	$-0.12	$-0.11	$-0.10	$-0.10	$-0.10
Analysts (Rev / EPS)	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1

Earnings Surprises

Recent Analyst Actions

Apr 24, 2026Craig-Hallum

Grace Therapeutics price target lowered to $4 from $11 at Craig-Hallum

Target:$4.00

+83.9%from $2.17

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance